| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 02/24/2005 | US20050042232 Treating infection to increase lymphocyte proliferation with cocktail of recombinant or synthetic antigens derived from hookworm, or chemically treated hookworm; tuberculosis, malaria, measles, tetanus, diphtheria, pertussis, polio; human T-cell leukemia/lymphoma and/or lymphadenopathy associated virus |
| 02/24/2005 | US20050042231 Useful in vaccines, and monoclonal antibodies against said immunogenic surface proteins; hybridoma cell line that produes said antibodies; use in diagnostic kits for determining presence, onset, or decrease in Leptospiral infection |
| 02/24/2005 | US20050042230 Administering respiratory syncytial virus G protein immunogen or fragment |
| 02/24/2005 | US20050042229 Influenza hemagglutinin and neuraminidase variants |
| 02/24/2005 | US20050042228 Method and pharmaceutical composition for the treatment of immune disorders |
| 02/24/2005 | US20050042227 drug biological conjugates used in the diagnosis, prophylaxis, or treatment of nervous system disorders or lysosomal storage diseases; drug delivery; blood brain barriers |
| 02/24/2005 | US20050042226 Treatment of chronic human viral hepatitis |
| 02/24/2005 | US20050042225 Compositions and methods for restoring sensitivity of tumor cells to antitumor therapy and inducing apoptosis |
| 02/24/2005 | US20050042222 Methods of diagnosing thyroid carcinoma |
| 02/24/2005 | US20050042219 Engineered Fab' fragment anti-tumor necrosis factor alpha in combination with disease modifying anti-rheumatic drugs |
| 02/24/2005 | US20050042215 Combination treatments for allergic disease comprising administering an anti-ige antibody and antiallergic compound |
| 02/24/2005 | US20050042214 Discovery of the microorganism that causes the human autoimmune disease, primary biliary cirrhosis |
| 02/24/2005 | US20050042209 Enhancing the induction apoptosis in a MUC1 expressing cancer cell by a pro-apoptotic drugs; antiproliferative agents |
| 02/24/2005 | US20050042208 Incubating precursor cell capable of differentiating to cytotoxic T cell with antigen presenting cell in presence of substance having binding activity to CD44, fibronectin, regulator of signal emitted by growth factor, and/or inhibitor of binding to growth factor receptor; immunotherapy |
| 02/24/2005 | US20050042203 Induction of antibodies against a hepatitis B surface antigen by sequential injection of bupivacaine and of a plasmid carrying a gene coding antigen; vaccine containing bare DNA is injected into host previously treated with substance capable of inducing coagulating necrosis of muscle fibers |
| 02/24/2005 | US20050042201 Synergistic mixture of glycoprotein and angiogenesis inhibitor comprising angiostatin, thrombostatin, endostatin, interferon, interferon-inducible factor 10, platelet factor, and/or cyclooxygenase inhibitor; antitumor and anticarcinogenic agents |
| 02/24/2005 | US20050042199 Comprising interleukin-2 (IL-2) and tlp peptides ( Tumour Liberated Particles) protein complexes; antitumor and anticarcinogenic agents; immunotherapy |
| 02/24/2005 | DE20122302U1 Variante des Modifizierten Vaccinia-Ankara-Virus Modified version of the vaccinia Ankara virus |
| 02/24/2005 | CA2762015A1 Methods for treating cardiovascular disease using a soluble ctla4 molecule |
| 02/24/2005 | CA2536235A1 Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics |
| 02/24/2005 | CA2535863A1 Polypeptides of streptococcus pyogenes |
| 02/24/2005 | CA2535812A1 Prkcs as modifiers of the beta catenin pathway and methods of use |
| 02/24/2005 | CA2535618A1 Compositions and vaccines containing antigen(s) of cryptosporidium parvum and of another pathogen |
| 02/24/2005 | CA2535515A1 Cd20-binding polypeptide compositions |
| 02/24/2005 | CA2535489A1 Antibodies against factor viii with modified glycosylation in the variable region |
| 02/24/2005 | CA2535156A1 Antibodies directed to parathyroid hormone (pth) and uses thereof |
| 02/24/2005 | CA2535071A1 Modified human igf-1r antibodies |
| 02/24/2005 | CA2535007A1 Nogo receptor antagonists |
| 02/24/2005 | CA2534875A1 Compositions and methods for manipulating levels of antigen-specific antibodies in a mammal |
| 02/24/2005 | CA2534563A1 Antibodies to c-met |
| 02/24/2005 | CA2534474A1 Methods for treating cardiovascular disease using a soluble ctla4 molecule |
| 02/24/2005 | CA2534215A1 Methods of therapy for chronic lymphocytic leukemia |
| 02/24/2005 | CA2533921A1 Binding constructs and methods for use thereof |
| 02/24/2005 | CA2533382A1 Etherified carbamate functional copolymers of isobutylene type monomers, and their use in curable compositions |
| 02/24/2005 | CA2532553A1 Methods for identifying compounds for regulating muscle mass or function using dopamine receptors |
| 02/24/2005 | CA2532027A1 Specific binding agents to hepatocyte growth factor |
| 02/24/2005 | CA2526339A1 Polyvalent immunogen |
| 02/24/2005 | CA2526146A1 Immunogenic compositions comprising venezuelan equine encephalitis virus replicon vectors and paramyxovirus protein antigens |
| 02/24/2005 | CA2525228A1 Molecules enhancing dermal delivery of influenza vaccines |
| 02/24/2005 | CA2524737A1 Antibodies that immunospecifically bind to trail receptors |
| 02/24/2005 | CA2524305A1 Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
| 02/23/2005 | EP1508615A1 Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics |
| 02/23/2005 | EP1508572A1 PROTEIN INDUCING CELL DEATH OF i HELICOBACTER PYLORI /i |
| 02/23/2005 | EP1508339A1 Tuberculosis vaccine |
| 02/23/2005 | EP1508338A1 Mycobacterial protein antigens for cancer therapy and vaccination |
| 02/23/2005 | EP1508337A2 Uses for eph receptor antagonists and agonists to treat vascular disorders |
| 02/23/2005 | EP1508047A2 Method for identifying immunoreactive peptides |
| 02/23/2005 | EP1507875A2 Assay for identifying inhibitors of fc gamma riii signaling |
| 02/23/2005 | EP1507863A1 Plasmid stabilisation in vivo |
| 02/23/2005 | EP1507861A2 Vaccines |
| 02/23/2005 | EP1507850A1 A method for generating antigen-presenting cells |
| 02/23/2005 | EP1507800A1 Use of monocarboxylate transporter protein for thyroid hormone transport |
| 02/23/2005 | EP1507794A2 Novel multimeric molecules, the preparation method thereof and use of same for the preparation of medicaments |
| 02/23/2005 | EP1507781A2 Process for preparing maytansinol |
| 02/23/2005 | EP1507562A1 Methods and compositions for radioimmunotherapy of brain and cns tumors |
| 02/23/2005 | EP1507560A1 Immune stimulating and controlling composition comprising bacterial chromosomal dna fragments and non-toxic lipopolysaccharides |
| 02/23/2005 | EP1507557A1 Methods and devices for targeting a site in a mammal and for removing species from a mammal |
| 02/23/2005 | EP1507556A2 Calicheamicin derivative-carrier conjugates |
| 02/23/2005 | EP1507555A2 Induction of antigen specific immunologic tolerance |
| 02/23/2005 | EP1507551A2 The functional role and potential therapeutic use of pacap, vip and maxadilan in relation to adult neural stem or progenitor cells |
| 02/23/2005 | EP1507547A2 Peptides for regulation of urokinase (upa) and tissue type (tpa) plasminogen activator and method of optimizing therapeutic efficacy |
| 02/23/2005 | EP1507546A2 Methods of using 22417, a novel human aminoprotease family member |
| 02/23/2005 | EP1507540A2 Nucleic acid vaccines using tumor antigen encoding nucleic acids with cytokine adjuvant encoding nucleic acid |
| 02/23/2005 | EP1507517A1 Microparticles bearing cells and active substances |
| 02/23/2005 | EP1175224B1 Pegylated interferon alfa-ccr5 antagonist combination hiv therapy |
| 02/23/2005 | EP1029549B1 Formulation of nucleic acids and acemannan |
| 02/23/2005 | EP0783524B1 Peptides and pharmaceutical compositions comprising them |
| 02/23/2005 | EP0689454B2 Vaccine compositions containing 3-o deacylated monophosphoryl lipid a |
| 02/23/2005 | CN1585778A Modified anti-TNF alpha antibody |
| 02/23/2005 | CN1585651A Methods of sterilizing biological materials containing non-aqueous solvents |
| 02/23/2005 | CN1583792A Vitellus immune globulin for preventing prawn virus, tis preparing method and use thereof |
| 02/23/2005 | CN1583171A Preparation of immuno-stimulation composition for hemolycin in monad |
| 02/23/2005 | CN1190491C PRV-gene and use thereof |
| 02/23/2005 | CN1190198C Modulation of TH1/TH2 cytokine expression by Ribavirin and Ribavirin analogs activated T-lymphocytes |
| 02/22/2005 | US6858724 Used as anti-tumor agents and/or anti-HIV agents having immunostimulate activities; inversion of OR2 to OR1 in glucopyranose derivtives (R1= H or acetyl, R2= a leaving group such as tosylate, trifluoromesylate or methanesulfonate |
| 02/22/2005 | US6858710 Compositions and methods for the therapy and diagnosis of ovarian cancer |
| 02/22/2005 | US6858706 Polypeptide comprising the amino acid of an N-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof |
| 02/22/2005 | US6858590 With an antigen that has an epitope of hepatitis c virus |
| 02/22/2005 | US6858580 Immobilization of drugs |
| 02/22/2005 | US6858578 Chimeric proteins for use in transport of a selected substance into cells |
| 02/22/2005 | US6858420 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 02/22/2005 | US6858407 Nucleotide sequences coding polypetide for use in the treatment, prevention and diagnosis of gastrointestinal and apoptosis disorders |
| 02/22/2005 | US6858386 Using cancer marker protein to detect, classify, evaluate and prevent cell proliferative disorders |
| 02/22/2005 | US6858385 Pseudorabies virus protein |
| 02/22/2005 | US6858211 Vaccines against Escherichia coli O157 infection |
| 02/22/2005 | US6858210 For inducing tolerance in an individual; bind to anti-cardiolipin ( beta 2GPI-dependent antiphospholipid) |
| 02/22/2005 | US6858209 Means for detecting bacteria of the taylorella equigenitalis species and their biological applications |
| 02/22/2005 | US6858207 Methods and materials relating to novel CD39-like polypeptides |
| 02/22/2005 | US6858199 High efficient delivery of a large therapeutic mass aerosol |
| 02/22/2005 | CA2150251C Lyospheres comprising gonadotropin |
| 02/22/2005 | CA2093022C Targeted immunostimulation with bispecific reagents |
| 02/17/2005 | WO2005014862A1 Methods of producing inflenza vaccine compositions |
| 02/17/2005 | WO2005014838A1 Chimeric antigens for breaking host tolerance to foreign antigens |
| 02/17/2005 | WO2005014819A1 Esophageal cancer antigen and utilization thereof |
| 02/17/2005 | WO2005014818A1 Gene overexpressed in cancer |
| 02/17/2005 | WO2005014816A1 Antigens for immunocontraception |
| 02/17/2005 | WO2005014803A1 West nile virus vaccine |
| 02/17/2005 | WO2005014778A2 Dna vaccine expressing ha1 of equine-2 influenza virus |
| 02/17/2005 | WO2005014776A2 Use of beta-glucans against biological warfare weapons and pathogens including anthrax |
| 02/17/2005 | WO2005014654A2 Product comprising a c4bp core protein and a monomeric antigen, and its use |